Innovation “Crisis” And Health Care Reform: Lilly CEO Urges Change In Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Lechleiter editorial, Chamber of Commerce appearance include warnings about adverse effects on innovation; “Odyssey Project” launched to press similar themes.
You may also be interested in...
Pharma Share Of Health Reform Cost Savings To Come From Drug Access, Compliance, Personalized Medicine
As stakeholders pledge to reduce health system growth by $2 trillion over 10 years, Rep. Dingell urges support for public plan; Sen. Grassley wants more “concrete” proposals, CBO score.
Accelerated Approval Is For Patients, Not Sponsors – US FDA’s Pazdur
Biotech sponsors understandably discuss accelerated approval as an important consideration in development plans. But the head of the US FDA oncology program has a reminder for them: the pathway is intended to serve patients – not drug companies.
The Long And Short Of Accelerated Approval Accountability In US
The latest accelerated approval withdrawals in the US are milestones for accountability in the program – most notably with the withdrawal of an antimicrobial with confirmatory studies more than a decade overdue.